Empagliflozin as an Alternative to Metformin for Antipsychotic‐Related Weight Gain: Double‐Blind Randomized Controlled Trial
Human Psychopharmacology: Clinical and Experimental · 2026-05 · 41 (3)
DOI: 10.1002/hup.70047 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 14.05.2026. Verfasst von Atena Dolati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Antipsychotic Agents, Glucosides, Metformin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences, Hamadan University of Medical Sciences.
Abstract (Originalsprache)
Background
Weight gain and metabolic disturbances are common adverse effects of antipsychotic medications such as clozapine and olanzapine. Beyond their primary role in glycemic control, sodium‐glucose cotransporter 2 (SGLT2) inhibitors have been associated with weight loss and improvements in various metabolic parameters. This study compared the efficacy and safety of empagliflozin and metformin in patients with antipsychotic‐induced weight gain (AIWG).
Methods
In this 12‐week, double‐blind, randomized controlled trial, 84 adults with schizophrenia or bipolar disorder and established weight gain from clozapine or olanzapine were assigned to receive either empagliflozin (10 mg daily) or metformin (1000 mg daily). The primary outcome was the percentage change in body weight from baseline to week 12. Secondary outcomes included changes in absolute body weight, body mass index (BMI), waist circumference, waist‐hip ratio, and the proportion of patients achieving ≥ 5% weight loss. Exploratory outcomes assessed changes in glycemic and lipid parameters, fasting insulin, and insulin resistance (HOMA‐IR). Safety was evaluated by monitoring adverse events, treatment discontinuations, and serious adverse events.
Results
Of the 84 randomized participants, 38 (90.5%) in the empagliflozin group and 39 (92.9%) in the metformin group completed the 12‐week study. Both treatments produced significant within‐group reductions in anthropometric measures (all p < 0.001) and there were no statistically significant differences between groups in the magnitude of change for body weight, BMI, waist circumference, hip circumference, or waist‐hip ratio (all p > 0.05). Both groups showed improvements in glycemic and lipid parameters, but empagliflozin resulted in significantly greater reductions in TG ( p = 0.004), fasting insulin ( p = 0.005), and HOMA‐IR ( p = 0.012), as well as a greater increase in HDL‐C ( p < 0.001) compared to metformin. The overall incidence of adverse effects was comparable (33.3% vs. 38.1%; p = 0.650), with no serious adverse events reported.
Conclusions
These findings suggest that empagliflozin is a promising alternative to metformin for managing metabolic complications in patients treated with clozapine or olanzapine. These findings warrant confirmation and further investigation in larger, long‐term studies.
Trial registration
The trial was registered prospectively at the Iranian Registry of Clinical Trials (IRCT) with the ID code IRCT20120215009014N538 on November 12, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Pharmacology & Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
- Medical Faculty, Hamadan University of Medical Science, Hamadan, Iran.
- Department of Epidemiology, School of Public and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, IR, Hamadan, Iran.
- Research Center of Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.
ORCID-Profile: Davoud Ahmadimoghaddam, Maryam Mehrpooya, Mona Doostizadeh
Förderung
- Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences
- Hamadan University of Medical Sciences
Zitieren
APA
Dolati, A., Ahmadimoghaddam, D., Zamanirafe, M., Rezaie, S., Khazaie, S., Mehrpooya, M., & Doostizadeh, M. (2026). Empagliflozin as an Alternative to Metformin for Antipsychotic‐Related Weight Gain: Double‐Blind Randomized Controlled Trial. Human Psychopharmacology: Clinical and Experimental, 41(3). https://doi.org/10.1002/hup.70047
Vancouver
Dolati A, Ahmadimoghaddam D, Zamanirafe M, Rezaie S, Khazaie S, Mehrpooya M, et al. Empagliflozin as an Alternative to Metformin for Antipsychotic‐Related Weight Gain: Double‐Blind Randomized Controlled Trial. Human Psychopharmacology: Clinical and Experimental. 2026;41(3). doi:10.1002/hup.70047
BibTeX
@article{Dolati2026,
author = {Dolati, Atena and Ahmadimoghaddam, Davoud and Zamanirafe, Maryam and Rezaie, Shabnam and Khazaie, Salman and Mehrpooya, Maryam and Doostizadeh, Mona},
title = {Empagliflozin as an Alternative to Metformin for Antipsychotic‐Related Weight Gain: Double‐Blind Randomized Controlled Trial},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2026},
volume = {41},
number = {3},
doi = {10.1002/hup.70047}
}
EUVIMED